Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide in Relapsed/Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma
NCT01847235Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- May 2013
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in anaplastic oligodendroglioma (AO) and oligoastrocytoma, sponsored by Seoul National University Hospital. Primary endpoint: Progression-Free Survival at 6 months. Started May 2013; status: completed.
02
Drugs
temozolomide
03
Conditions
anaplastic oligodendroglioma (AO)oligoastrocytoma
Beyond the preview
Go deeper on NCT01847235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01847235.